Delivering through innovating cancer therapeutics
Defeating Cancer
Our Story
OurStory
Speratum Biopharma was founded to transform groundbreaking research into effective cancer treatments. Led by Dr. Christian Marín Müller, a pioneer in oncological biotechnology, our team combines expertise in molecular biology, nanotechnology, and precision medicine to address the urgent need for better patient outcomes. Despite advances in cancer research, many therapies still rely on broad-spectrum approaches with inconsistent results, leading to prolonged treatments.
At Speratum, we are changing this by developing miRNA-based therapies that target cancer at its core, offering more precise and effective solutions. Guided by scientific innovation and a commitment to saving lives, we are shaping a new era in cancer care—one where innovation drives real patient impact.
Precision Oncology: Turning Hope into Life-Changing Reality.
Precision Oncology: Turning Hope into Life-Changing Reality.
Our Mission
We are committed to delivering cutting-edge, targeted cancer therapies—swiftly, effectively, and with life-changing outcomes.
Our Vision
We envision a cancer-free world, where breakthrough therapies offer real hope and transformative change for every patient in need.
A future without cancer
A future without cancer
Speratum Biopharma is pioneering a new class of RNA interference (RNAi) therapeutics designed to inhibit dysregulated cellular pathways that drive cancer and other hard-to-treat diseases. Our precision strategy integrates the fine-tuned specificity of traditional siRNA with the multifaceted control mechanisms typically associated with microRNA—delivering a fulcrum-like therapeutic effect that is both powerful and broadly applicable.
Our proprietary platforms—Nano-In™ and NoPass™—enable targeted delivery and optimized expression, making RNAi a viable and superior solution for tackling solid tumors and other aggressive malignancies.
Beyond oncology, we are also exploring the expanded utility of our RNAi modulators in other genetically driven diseases, especially where existing therapies have fallen short.
This innovation stems from over a decade of foundational research in nucleic acid-based therapeutics. At Speratum, we push the boundaries of RNA science to transform patient outcomes and redefine the potential of precision medicine.
Our Technology
Our Technology
miR-198
Speratum Biopharma’s miR-198 represents a groundbreaking therapeutic scaffold, targeting pleiotropic mechanisms central to cancer progression. As a key tumor suppressor microRNA, miR-198 is notably downregulated in various cancers, offering a powerful therapeutic hypothesis for combating malignancies. By leveraging Speratum’s innovative platform technologies, the therapeutic potential of miR-198 is unlocked, enabling it to address a wide range of cancer types. miR-198 acts as a central control point, regulating critical processes that suppress tumor growth, inhibit cancer cell migration, and overcome drug resistance. This multifaceted approach positions miR-198 as a transformative tool in the fight against cancer, advancing precision oncology to new heights.
NoPass Design
The NoPass™ platform represents a next-generation innovation in RNA interference (RNAi) therapy design. It is built as a proprietary RNAi-based scaffold engineered to regulate complex, dysregulated signaling networks that drive cancer progression. Acting as a central control node, NoPass is designed to simultaneously suppress tumor growth, limit metastasis, and overcome resistance to therapy by targeting multiple oncogenic pathways in a coordinated, intelligent manner. What sets NoPass apart is its precision algorithmic design—a suite of proprietary tools that generate RNAi molecules with enhanced specificity, minimized off-target activity, and increased potency. These intelligently engineered molecules overcome the traditional limitations of RNA therapeutics, offering a more predictable, modular, and potent therapeutic output. NoPass orchestrates precision through intelligent RNAi engineering—delivering a level of therapeutic breadth typically associated with microRNA and the precision and targetability of siRNA, without being confined to either class.
Nano-In
The Nano-In™ Platform is a revolutionary drug delivery system. Utilizing a proprietary biocompatible polymer, Nano-In™ forms nanoparticles that precisely target cancer cells. This platform optimizes the delivery of nucleic acids directly to tumor sites, ensuring protection from degradation, maximizing potency, and minimizing off-target effects. The result is a delivery system that reduces toxicity while enhancing therapeutic impact, leading to safer and more effective treatments.
NM-198 Fully loaded
NM-198 is Speratum’s flagship RNAi candidate. Built on the combined strengths of NoPass™ and Nano-In™, this therapeutic platform targets multiple drivers of tumor biology—growth, invasion, and resistance—while ensuring safe and efficient delivery. The result is a novel RNAi-based treatment with the potential to redefine outcomes in precision oncology.
Our Approach
Our Approach
A First-of-Its-Kind Blueprint in Precision RNAi Oncology
Revolutionizing Cancer Treatment with Precision RNA Innovation
At Speratum Biopharma, we’re not just improving cancer treatment—we’re rewriting its molecular strategy. Our approach is the first of its kind: a fully integrated RNA interference (RNAi) platform built to intercept cancer at its most fundamental control points.
What sets us apart is the convergence of precision design and intelligent delivery—a dynamic system in which our NoPass™ platform engineers highly specific, multi-targeted RNAi molecules, while Nano-In™ ensures they reach their destination with surgical accuracy.
NM-198, our flagship candidate, doesn’t simply inhibit a single mutation—it acts as a regulatory fulcrum across multiple oncogenic pathways, achieving what no current RNA therapy has accomplished: coordinated control with minimal collateral damage.
This isn’t siRNA. It isn’t microRNA. It’s a new class of RNAi therapeutics—engineered for range, refined for precision, and designed to overcome the clinical dead-ends of the past.
We’re not following the path forward. We’re building it.
Join us in leading a new frontier in oncology—where cancer loses its grip at the source.
Revolutionizing Cancer Treatment with Precision RNA Innovation |
Choose your pathway
Our Publications
Our Publications
Meet the Executive Team
At Speratum Biopharma, our team includes pioneers in RNA-based medicine, precision oncology, and translational innovation. With decades of combined experience and a strong foundation in research, development, and commercialization, we are committed to building transformative therapies that make a real difference.
